Nan Y - Search Results

Year	Number of Results
1988	1
1992	2
1995	4
1996	2
1997	1
1999	2
2000	2
2003	1
2004	2
2005	6
2006	8
2007	9
2008	11
2009	18
2010	31
2011	29
2012	27
2013	30
2014	23
2015	35
2016	53
2017	58
2018	67
2019	80
2020	87
2021	87
2022	122
2023	152
2024	173
2025	140

1

Lysine vitcylation is a vitamin C-derived protein modification that enhances STAT1-mediated immune response.

He X, Wang Q, Cheng X, Wang W, Li Y, Nan Y, Wu J, Xiu B, Jiang T, Bergholz JS, Gu H, Chen F, Fan G, Sun L, Xie S, Zou J, Lin S, Wei Y, Lee J, Asara JM, Zhang K, Cantley LC, Zhao JJ. He X, et al. Among authors: nan y. Cell. 2025 Apr 3;188(7):1858-1877.e21. doi: 10.1016/j.cell.2025.01.043. Epub 2025 Feb 28. Cell. 2025. PMID: 40023152 Free PMC article.

2

Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms.

Chen G, Gou B, Du Y, Zhou Z, Bai Y, Yang Y, Nan Y, Yuan L. Chen G, et al. Among authors: nan y. Phytomedicine. 2025 Jul 25;143:156892. doi: 10.1016/j.phymed.2025.156892. Epub 2025 May 24. Phytomedicine. 2025. PMID: 40446574 Free article.

3

Inhibiting Mitochondrial Damage for Efficient Treatment of Cerebral Ischemia-Reperfusion Injury Through Sequential Targeting Nanomedicine of Neuronal Mitochondria in Affected Brain Tissue.

Wang S, Shi X, Xiong T, Chen Q, Yang Y, Chen W, Zhang K, Nan Y, Huang Q, Ai K. Wang S, et al. Among authors: nan y. Adv Mater. 2024 Dec;36(50):e2409529. doi: 10.1002/adma.202409529. Epub 2024 Nov 6. Adv Mater. 2024. PMID: 39501980

4

Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022).

You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J, Zhuang H; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. You H, et al. Among authors: nan y. J Clin Transl Hepatol. 2023 Nov 28;11(6):1425-1442. doi: 10.14218/JCTH.2023.00320. Epub 2023 Aug 15. J Clin Transl Hepatol. 2023. PMID: 37719965 Free PMC article.

5

OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.

Nan Y, Wu X, Luo Q, Chang W, Zhao P, Zhang L, Liu Z. Nan Y, et al. Proc Natl Acad Sci U S A. 2024 May 7;121(19):e2315348121. doi: 10.1073/pnas.2315348121. Epub 2024 May 3. Proc Natl Acad Sci U S A. 2024. PMID: 38701117 Free PMC article.

6

Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).

Fan JG, Xu XY, Yang RX, Nan YM, Wei L, Jia JD, Zhuang H, Shi JP, Li XY, Sun C, Li J, Wong VW, Duan ZP; Chinese Society of Hepatology, Chinese Medical Association. Fan JG, et al. Among authors: nan ym. J Clin Transl Hepatol. 2024 Nov 28;12(11):955-974. doi: 10.14218/JCTH.2024.00311. Epub 2024 Nov 4. J Clin Transl Hepatol. 2024. PMID: 39544247 Free PMC article.

7

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.

Eslam M, Fan JG, Yu ML, Wong VW, Cua IH, Liu CJ, Tanwandee T, Gani R, Seto WK, Alam S, Young DY, Hamid S, Zheng MH, Kawaguchi T, Chan WK, Payawal D, Tan SS, Goh GB, Strasser SI, Viet HD, Kao JH, Kim W, Kim SU, Keating SE, Yilmaz Y, Kamani L, Wang CC, Fouad Y, Abbas Z, Treeprasertsuk S, Thanapirom K, Al Mahtab M, Lkhagvaa U, Baatarkhuu O, Choudhury AK, Stedman CAM, Chowdhury A, Dokmeci AK, Wang FS, Lin HC, Huang JF, Howell J, Jia J, Alboraie M, Roberts SK, Yoneda M, Ghazinian H, Mirijanyan A, Nan Y, Lesmana CRA, Adams LA, Shiha G, Kumar M, Örmeci N, Wei L, Lau G, Omata M, Sarin SK, George J. Eslam M, et al. Among authors: nan y. Hepatol Int. 2025 Apr;19(2):261-301. doi: 10.1007/s12072-024-10774-3. Epub 2025 Feb 27. Hepatol Int. 2025. PMID: 40016576

8

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.

Nan Y, Bai Y, Hu X, Zhou K, Wu T, Zhu A, Li M, Dou Z, Cao Z, Zhang X, Xu S, Zhang Y, Lin J, Zeng X, Fan J, Zhang X, Wang X, Ju D. Nan Y, et al. J Immunother Cancer. 2024 Sep 3;12(9):e009236. doi: 10.1136/jitc-2024-009236. J Immunother Cancer. 2024. PMID: 39231544 Free PMC article.

9

Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta₂ C Modified with Chondroitin Sulfate (TACS).

Song X, Huang Q, Yang Y, Ma L, Liu W, Ou C, Chen Q, Zhao T, Xiao Z, Wang M, Jiang Y, Yang Y, Zhang J, Nan Y, Wu W, Ai K. Song X, et al. Among authors: nan y. Adv Mater. 2023 Sep;35(36):e2301585. doi: 10.1002/adma.202301585. Epub 2023 Jul 23. Adv Mater. 2023. PMID: 37224059

10

HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity.

Nan Y, Luo Q, Wu X, Chang W, Zhao P, Liu S, Liu Z. Nan Y, et al. Mol Ther. 2023 Feb 1;31(2):552-568. doi: 10.1016/j.ymthe.2022.10.006. Epub 2022 Oct 17. Mol Ther. 2023. PMID: 36245126 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,134 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,134 results

Results by year